Similar Search Results

Organisation of asthma care: What difference does it make? A systematic review of the literature

Eastwood, Alison J.; Sheldon, Trevor A. - In: Quality in health care 5 (1996) 3, pp. 134-143

Persistent link: https://www.econbiz.de/10007253198

Preventing falls and subsequent injury in older people

Oakley, Ann; France Dawson, Merry; Holland, Janet; … - In: Quality in health care 5 (1996) 4, pp. 243-249

Persistent link: https://www.econbiz.de/10007252699

Adjusting physician payment for malpractice risk

Brennan, Troyen A.; Eastwood, Alison J.; Newhouse, Joseph P. - 1993

Persistent link: https://www.econbiz.de/10008730269

Vemurafenib for the Treatment of Locally Advanced or Metastatic BRAF V600 Mutation-Positive Malignant Melanoma: A NICE Single Technology Appraisal

Beale, Sophie; Dickson, Rumona; Bagust, Adrian; … - In: PharmacoEconomics 31 (2013) 12, pp. 1121-1129

Vemurafenib is an oral BRAF inhibitor licenced for the treatment of locally advanced or metastatic BRAF V600-mutation positive malignant melanoma. The manufacturer of vemurafenib, Roche Products Limited, was invited by the National Institute for Health and Care Excellence (NICE) to submit...

Persistent link: https://www.econbiz.de/10011001752

Erlotinib Monotherapy for the Maintenance Treatment of Non-Small Cell Lung Cancer after Previous Platinum-Containing Chemotherapy: A NICE Single Technology Appraisal

Dickson, Rumona; Bagust, Adrian; Boland, Angela; … - In: PharmacoEconomics 29 (2011) 12, pp. 1051-1062

The UK National Institute for Health and Clinical Excellence (NICE) invited the manufacturer of erlotinib (Roche) to submit evidence for the clinical and cost effectiveness of erlotinib as monotherapy for the maintenance treatment of patients with non-small cell lung cancer (NSCLC) and stable...

Persistent link: https://www.econbiz.de/10010614353

Management of cataract

Dickson, Rumona; Eastwood, Alison; Gill, Paramjit; … - In: Quality in health care 5 (1996) 3, pp. 180-185

Persistent link: https://www.econbiz.de/10007253192

Cetuximab for Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck: A NICE Single Technology Appraisal

Bagust, Adrian; Greenhalgh, Janette; Boland, Angela; … - In: PharmacoEconomics 28 (2010) 6, pp. 439-448

The National Institute for Health and Clinical Excellence (NICE) invited the manufacturer of cetuximab (Merck Serono) to submit evidence for the clinical and cost effectiveness of cetuximab in combination with platinum-based chemotherapy (CTX) for the treatment of patients with recurrent and/or...

Persistent link: https://www.econbiz.de/10008467350

A thematic analysis of the strengths and weaknesses of manufacturers’ submissions to the NICE Single Technology Assessment (STA) process

Carroll, Christopher; Kaltenthaler, Eva; FitzGerald, Patrick - In: Health Policy 102 (2011) 2, pp. 136-144

The NICE Single Technology Appraisal (STA) process in the UK has been underway for five years. Evidence Review Groups (ERGs) critically appraise submissions from manufacturers on the clinical and cost effectiveness of new technologies. This study analysed the ERGs’ assessment of the strengths...

Persistent link: https://www.econbiz.de/10010576997

Pertuzumab in Combination with Trastuzumab and Docetaxel for the Treatment of HER2-Positive Metastatic or Locally Recurrent Unresectable Breast Cancer

Fleeman, Nigel; Bagust, Adrian; Beale, Sophie; Dwan, Kerry - In: PharmacoEconomics 33 (2015) 1, pp. 13-23

The National Institute for Health and Care Excellence (NICE) invited the manufacturer of pertuzumab (Roche) to submit evidence for the clinical and cost effectiveness of pertuzumab + trastuzumab + docetaxel for the treatment of human epidermal growth factor receptor 2-positive (HER2+)...

Persistent link: https://www.econbiz.de/10011152265

Concentration and choice in healthcare

Ferguson, Brian S. (contributor); … - 1997

Persistent link: https://www.econbiz.de/10000964453